Incyte


Incyte Says FDA Grants Priority Review For Eczema Cream; Street Sees 20% Upside

Incyte announced that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of its ruxolitinib …

Here Are My Top 3 Biotech Stocks

By Genia Turanova There’s nothing like cash to show how successful a company has been. When a fledgling enterprise first turns cash-flow positive …

Incyte (INCY) Shares Remain Attractive, Says Top Analyst

This morning, Incyte (NASDAQ:INCY) announced that the company’s ECHO-301 study comparing epacadostat in combination with pembrolizumab with pembrolizumab alone in melanoma failed to …

What’s in Store for Incyte Corporation (INCY) After “Big Time” Clinical Miss? Reni Benjamin Chimes In

Raymond James’ Reni Benjamin may scale back his expectations on INCY, but still bets on 24% in return potential for shares.

Stock Update (NASDAQ:INCY): Lilly and Incyte Corporation Unveil Detailed Data on Two Pivotal Studies of Baricitinib in Rheumatoid Arthritis

Eli Lilly and Company and Incyte Corporation (NASDAQ:INCY) announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for …

Company Update (NASDAQ:INCY): Incyte Corporation Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings

Incyte Corporation (NASDAQ:INCY) announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis and independent investigators, …

Agenus Prices Spike after Partnership with Incyte

Agenus, Inc (NASDAQ: AGEN) announced a global alliance with Incyte Corp. (NASDAQ: INCY) to develop cancer therapies.

Cowen Maintains Outperform On Incyte Following Jakafi FDA Approval For Polycythemia Vera

Cowen analyst Eric Schmidt maintained an Outperform rating on Incyte (NASDAQ:INCY), following the news that the company’s Jakafi gained FDA approval for the treatment …

Brean Capital Remains Positive On Incyte Following 3Q14 Results

In a research report issued yesterday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Incyte (NASDAQ:INCY) and slightly raised his price …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts